Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

PAGE II (2013-2019) seeks to expand understanding gained during PAGE I and similar studies of how ancestry-specific differences in allele frequencies and LD may explain differences in risks of common traits and conditions. Recent studies have identified rare genetic variants that are likely to contribute to common diseases and traits and observed that rare variants likely to be functional, such as those in coding and regulatory regions, tend to be population-specific. PAGE II has genotyped over 50,000 samples using MEGA, an Illumina high density custom exomechip array. The MEGA data is being imputed in PAGE to the 1000 Genomes panel. PAGE also sequenced 1,000 samples representative of 21 populations from the Americas. PAGE has harmonized phenotype data for ~300 trait variables. These datasets will be analyzed to continue emphasis on characterizing population-level disease risks in non-European-descent individuals. Cohorts in PAGE II are: CALiCo (Causal Variants Across the Life Course, a consortium of ARIC, CARDIA, HCHS/SOL, Strong Heart Studies), ISMMS (Mount Sinai BioMe Biobank), MEC (Multiethnic Cohort), WHI (Women's Health Initiative), and Stanford University (PAGE Global Reference Panel). Genotyping services were provided by the Center for Inherited Disease Research (CIDR) and sequence data were provided by the McDonnell Genome Institute at Washington University School of Medicine.

PAGE I (2008-2013): The first phase of PAGE examined putative causal genetic variants across approximately 100,000 African Americans, Asian Americans, American Indians, European Americans, Hispanic Americans, and Native Hawaiians from four groups representing nine large U.S.-based cohorts. Two genotyping approaches were employed - targeted genotyping of selected SNPs identified in genome-wide association studies of common disease, and a large-scale effort focused on the Metabochip array, which facilitated trans-ethnic fine mapping of several diseases of public health importance. Cohorts in PAGE I were: CALiCo (Causal Variants Across the Life Course, a consortium of ARIC, CARDIA, CHS, HCHS/SOL, Strong Heart Cohort Study, Strong Heart Family Study), EAGLE (Epidemiologic Architecture for Genes Linked to Environment, based on 3 National Health and Nutrition Examination Surveys (NHANES)), MEC (Multiethnic Cohort) and WHI (Women's Health Initiative).

Logistical and scientific support is provided by the PAGE Coordinating Center and the NHGRI Division of Genomic Medicine. PAGE II is funded by the NHGRI and the NIMHD.

To access PAGE studies currently available in dbGaP, please click on the links below.Please note that some PAGE studies belong to larger cohorts and have been included as PAGE substudies. For those studies, there is an additional link to the parent study.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • PAGE II Principal Investigators
    • Kari North, PhD. University of North Carolina, Chapel Hill, NC, USA.
    • Charles Kooperberg, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Ulrike Peters, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Christopher Haiman, ScD. University of Southern California, Los Angeles, USA.
    • Tara Matise, PhD. Rutgers University, Piscataway, NJ, USA.
    • Steven Buyske, PhD. Rutgers University, Piscataway, NJ, USA.
    • Ruth Loos, PhD. Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • PAGE I Principal Investigators
    • Dana Crawford, PhD. Vanderbilt University, Nashville, TN, USA.
    • Gerardo Heiss, PhD. University of North Carolina, Chapel Hill, NC, USA.
    • Charles Kooperberg, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Loic Le Marchand, PhD. University of Hawaii, Honolulu, HI, USA.
    • Tara Matise, PhD. Rutgers University, Piscataway, NJ, USA.
  • PAGE II Funding Source
    • U01HG007397. National Institutes of Health, Bethesda, MD, USA.
    • U01HG007416. National Institutes of Health, Bethesda, MD, USA.
    • U01HG007376. National Institutes of Health, Bethesda, MD, USA.
    • U01HG007417. National Institutes of Health, Bethesda, MD, USA.
    • U01HG007419. National Institutes of Health, Bethesda, MD, USA.
    • U54HG003079. National Institutes of Health, Bethesda, MD, USA.
    • HHSN268201200008I. National Institutes of Health, Bethesda, MD, USA.
  • PAGE I Funding Source
    • U01HG004798. National Institutes of Health, Bethesda, MD, USA.
    • U01HG004803. National Institutes of Health, Bethesda, MD, USA.
    • U01HG004802. National Institutes of Health, Bethesda, MD, USA.
    • U01HG004790. National Institutes of Health, Bethesda, MD, USA.
    • U01HG004801. National Institutes of Health, Bethesda, MD, USA.
  • Genotyping Center
    • Johns Hopkins University Center for Inherited Disease Research (CIDR), Baltimore, MD, USA.
  • Funding Source for CIDR Genotyping
    • HHSN268201200008I, NIH contract "High throughput genotyping for studying the genetic contributions to human disease". National Institutes of Health, Bethesda, MD, USA.
  • Genotyping Quality Control
    • Genetics Coordinating Center. Department of Biostatistics, University of Washington, WA, USA.